Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.

Nicole G Newcombe1, E Susanne Johansson, Gough Au

  • 1The Picornaviral Research Unit, School of Biomedical Sciences, Faculty of Health, The University of Newcastle, Newcastle, New South Wales 2300, Australia.

Journal of Virology
|January 15, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.

NPJ vaccines·2025
Same author

Metagenomic analysis of Mesolithic chewed pitch reveals poor oral health among stone age individuals.

Scientific reports·2024
Same author

Saffold virus infection in elderly people with acute gastroenteritis in Sweden.

Journal of medical virology·2020
Same author

Early Entry Events in Echovirus 30 Infection.

Journal of virology·2020
Same author

Slow Infection due to Lowering the Amount of Intact versus Empty Particles Is a Characteristic Feature of Coxsackievirus B5 Dictated by the Structural Proteins.

Journal of virology·2019
Same author

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2019

Clinical Coxsackievirus A21 (CVA21) isolates show enhanced ability to use decay-accelerating factor (DAF) for cell entry compared to lab strains. Some CVA21 isolates can infect cells using only DAF, suggesting altered viral pathogenesis.

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Human enteroviruses exhibit varied cellular receptor usage between clinical and laboratory strains.
  • Coxsackievirus A21 (CVA21) prototype strains use decay-accelerating factor (DAF) and intercellular adhesion molecule 1 (ICAM-1).

Purpose of the Study:

  • To compare the cellular receptor interactions of low-passage CVA21 clinical isolates with the CVA21 prototype strain.
  • To investigate the role of DAF and ICAM-1 in CVA21 infection by clinical isolates.

Main Methods:

  • Cell transfection and radiolabeled binding assays were used to assess CVA21-receptor interactions.
  • Antibody cross-linking of DAF was employed to study viral susceptibility.
  • P1 genomic region sequencing was performed to identify genetic variations.

Related Experiment Videos

Main Results:

  • CVA21 clinical isolates demonstrated dual-receptor usage of DAF and ICAM-1.
  • High-level coexpression of DAF and ICAM-1 inhibited CVA21 attachment.
  • Three clinical isolates infected DAF-expressing cells without ICAM-1 or DAF-antibody cross-linking.
  • Sequence analysis revealed coding changes in the P1 region of clinical isolates.

Conclusions:

  • Community-circulating CVA21 strains can infect cells via DAF or ICAM-1 alone.
  • These interactions potentially expand tissue tropism and influence viral pathogenesis.
  • Observed variations in receptor usage may be linked to genetic changes in circulating CVA21 strains.